Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said pursuant to a global alliance inked in January 2014, Paris-based Sanofi SA’s Genzyme unit elected to opt in to co-develop and co-commercialize fitusiran, an RNAi therapeutic for the treatment of hemophilia and rare bleeding disorders (RBD), in the U.S., Canada and Western Europe.